Liver Cancer - Pipeline Review, H2 2013


#172040

616pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Liver Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. Liver Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Liver Cancer.
  • A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Liver Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 7
Liver Cancer Overview 8
Therapeutics Development 9
Liver Cancer Therapeutics under Development by Companies 11
Liver Cancer Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 23
Mid Clinical Stage Products 24
Early Clinical Stage Products 25
Discovery and Pre-Clinical Stage Products 26
Liver Cancer Therapeutics – Products under Development by Companies 27
Liver Cancer Therapeutics – Products under Investigation by Universities/Institutes 37
Companies Involved in Liver Cancer Therapeutics Development 39
Liver Cancer – Therapeutics Assessment 140
Drug Profiles 148
Liver Cancer Therapeutics – Drug Profile Updates 428
Liver Cancer Therapeutics – Discontinued Products 578
Liver Cancer Therapeutics - Dormant Products 579
Liver Cancer – Product Development Milestones 586

Appendix 596

Number of Products Under Development for Liver Cancer, H2 2013 28
Products under Development for Liver Cancer Comparative Analysis, H2 2013 29
Number of Products under Development by Companies, H2 2013 31
Number of Products under Development by Companies, H2 2013 (Contd..1) 32
Number of Products under Development by Companies, H2 2013 (Contd..2) 33
Number of Products under Development by Companies, H2 2013 (Contd..3) 34
Number of Products under Development by Companies, H2 2013 (Contd..4) 35
Number of Products under Development by Companies, H2 2013 (Contd..5) 36
Number of Products under Development by Companies, H2 2013 (Contd..6) 37
Number of Products under Development by Companies, H2 2013 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2013 40
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 41
Comparative Analysis by Late Stage Development, H2 2013 42
Comparative Analysis by Mid Clinical Stage Development, H2 2013 43
Comparative Analysis by Early Clinical Stage Development, H2 2013 44
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 45
Products under Development by Companies, H2 2013 46
Products under Development by Companies, H2 2013 (Contd..1) 47
Products under Development by Companies, H2 2013 (Contd..2) 48
Products under Development by Companies, H2 2013 (Contd..3) 49
Products under Development by Companies, H2 2013 (Contd..4) 50
Products under Development by Companies, H2 2013 (Contd..5) 51
Products under Development by Companies, H2 2013 (Contd..6) 52
Products under Development by Companies, H2 2013 (Contd..7) 53
Products under Development by Companies, H2 2013 (Contd..8) 54
Products under Development by Companies, H2 2013 (Contd..9) 55
Products under Investigation by Universities/Institutes, H2 2013 56
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 57
Bristol-Myers Squibb Company, H2 2013 58
Boehringer Ingelheim GmbH, H2 2013 59
F. Hoffmann-La Roche Ltd., H2 2013 60
Celsion Corporation, H2 2013 61
Biogen Idec Inc., H2 2013 62
Amgen Inc., H2 2013 63
AstraZeneca PLC, H2 2013 64
Eli Lilly and Company, H2 2013 65
GlaxoSmithKline plc, H2 2013 66
Tekmira Pharmaceuticals Corp., H2 2013 67
Inovio Biomedical Corporation, H2 2013 68
Bavarian Nordic A/S, H2 2013 69
MedImmune LLC, H2 2013 70
Daiichi Sankyo Company, Ltd, H2 2013 71
Bioneer Corporation, H2 2013 72
Takeda Pharmaceutical Company Limited, H2 2013 74
Delcath Systems, Inc., H2 2013 75
Light Sciences Oncology, Inc., H2 2013 76
ZIOPHARM Oncology, Inc., H2 2013 77
Novartis AG, H2 2013 78
CK Life Sciences Intl., (Holdings) Inc., H2 2013 79
Eisai Co., Ltd., H2 2013 80
Kowa Company, Ltd., H2 2013 81
MDRNA, Inc., H2 2013 82
Ono Pharmaceutical Co., Ltd., H2 2013 83
Pfizer Inc., H2 2013 84
SuperGen, Inc., H2 2013 85
Taiho Pharmaceutical Co., Ltd., H2 2013 86
Silence Therapeutics plc., H2 2013 87
Aduro BioTech, H2 2013 88
Bayer AG, H2 2013 89
4SC AG, H2 2013 90
Active Biotech AB, H2 2013 91
IMMUNOMEDICS, INC, H2 2013 92
Can-Fite BioPharma Ltd., H2 2013 93
Ligand Pharmaceuticals Incorporated, H2 2013 94
MultiCell Technologies, Inc., H2 2013 95
Northwest Biotherapeutics, Inc., H2 2013 96
Nymox Pharmaceutical Corporation, H2 2013 97
Cleveland BioLabs, Inc., H2 2013 98
OXiGENE, Inc., H2 2013 99
Curis, Inc., H2 2013 101
ARQULE, INC, H2 2013 102
Alnylam Pharmaceuticals, Inc, H2 2013 103
TopoTarget A/S, H2 2013 104
CytRx Corporation, H2 2013 105
Transgene SA, H2 2013 106
Senesco Technologies, Inc., H2 2013 107
Immuron Limited, H2 2013 108
Progen Pharmaceuticals Limited, H2 2013 109
Innocell Corporation, H2 2013 110
Threshold Pharmaceuticals, Inc., H2 2013 111
Provectus Pharmaceuticals, Inc., H2 2013 112
Synta Pharmaceuticals Corp., H2 2013 113
BioAlliance Pharma SA, H2 2013 114
Simcere Pharmaceutical Group, H2 2013 115
Transgene Biotek Ltd, H2 2013 116
Raptor Pharmaceuticals Corp., H2 2013 117
Nanobiotix, H2 2013 118
Dicerna Pharmaceuticals, Inc., H2 2013 119
Sunway Biotech Co.,Ltd, H2 2013 120
Cancer Research Technology Limited, H2 2013 121
Antisense Pharma GmbH, H2 2013 122
Chipscreen Biosciences Ltd, H2 2013 124
Nerviano Medical Sciences S.r.l., H2 2013 125
Provecs Medical GmbH, H2 2013 128
GenSpera, Inc., H2 2013 129
NormOxys, Inc., H2 2013 130
Mondobiotech Holding AG, H2 2013 131
Jennerex Biotherapeutics, Inc., H2 2013 132
Advenchen Laboratories, LLC, H2 2013 133
AndroScience Corporation, H2 2013 134
Onconova Therapeutics, Inc, H2 2013 135
MolMed S.p.A., H2 2013 136
Mirna Therapeutics, Inc., H2 2013 137
Omeros Corporation, H2 2013 138
China Medical System Holdings Limited, H2 2013 139
Welichem Biotech Inc., H2 2013 140
Oncolys BioPharma Inc., H2 2013 141
Immunocore Limited., H2 2013 142
Taiwan Liposome Company, H2 2013 143
Sirnaomics, Inc., H2 2013 144
CureTech Ltd., H2 2013 145
Viventia Biotechnologies Inc., H2 2013 146
Vicus Therapeutics, LLC, H2 2013 147
TRACON Pharmaceuticals, Inc., H2 2013 148
KAHR medical Ltd., H2 2013 149
Keystone Nano, Inc., H2 2013 150
Regulus Therapeutics Inc., H2 2013 151
Galaxy Biotech, LLC, H2 2013 152
KAEL-GemVax, H2 2013 154
Therapure Biopharma Inc., H2 2013 155
Polaris Group, H2 2013 156
IkerChem S.L., H2 2013 157
Gradalis Inc., H2 2013 158
Assessment by Monotherapy Products, H2 2013 159
Assessment by Combination Products, H2 2013 160
Assessment by Stage and Route of Administration, H2 2013 163
Assessment by Stage and Molecule Type, H2 2013 166
Liver Cancer Therapeutics Drug Profile Updates 447
Liver Cancer Therapeutics Discontinued Products 597
Liver Cancer Therapeutics Dormant Products 598
Liver Cancer Therapeutics Dormant Products (Contd..1) 599
Liver Cancer Therapeutics Dormant Products (Contd..2) 600
Liver Cancer Therapeutics Dormant Products (Contd..3) 601
Liver Cancer Therapeutics Dormant Products (Contd..4) 602
Liver Cancer Therapeutics Dormant Products (Contd..5) 603
Liver Cancer Therapeutics Dormant Products (Contd..6) 604

Number of Products under Development for Liver Cancer, H2 2013 28
Products under Development for Liver Cancer – Comparative Analysis, H2 2013 29
Products under Development by Companies, H2 2013 30
Products under Investigation by Universities/Institutes, H2 2013 39
Late Stage Products, H2 2013 42
Mid Clinical Stage Products, H2 2013 43
Early Clinical Stage Products, H2 2013 44
Discovery and Pre-Clinical Stage Products, H2 2013 45
Assessment by Monotherapy Products, H2 2013 159
Assessment by Combination Products, H2 2013 160
Assessment by Route of Administration, H2 2013 161
Assessment by Stage and Route of Administration, H2 2013 162
Assessment by Molecule Type, H2 2013 164
Assessment by Stage and Molecule Type, H2 2013 165